The launch of the 750mcg teriparatide product in Australia has encountered restricted uptake. Currently, this larger dose injection is mainly designated for individuals with significant osteoporosis who have not reacted with other therapies . Access can be difficult due to specialist referral requirements and restricted dispensary distribution . Wh